Adjuvant chemotherapy in resected non small cell lung cancer: preliminary results about 8 cases.

##plugins.themes.academic_pro.article.sidebar##

Published Jun 22, 2010
Download
pdf
Vol. 88 No. 7 (2010): Issue Jul 2010

##plugins.themes.academic_pro.article.main##

Leila El Fekih
Soraya Fenniche
Hela Hassene
Dalenda Belhabib
Service de pneumologie Ibn Nafiss. Hôpital Abderrhmane MAMI de L'ARIANA
Hajer Ben Abdelghaffar
Tarek Kilani
Faouzi El Mezni
Mohamed Lamine Megdiche

Abstract

Aim: Report the preliminary results of adjuvant chemotherapy in patients surgically treated for non small lung cancer.
Methods : It’s a prospective study about 12 patients surgically treated between January 2005 and December 2007.8 patients had benefit of adjuvant chemotherapy. The protocol had been based at 4 cycles of Cisplatine
Results: Our 8 men patients, aged for the mean of 59 years with a Performans Status at 1, had benefit of adjuvant chemotherapy after curative surgery. Six patients considered us II B stage, had benefit immediately for surgically treatment. Adjuvant chemotherapy protocol had been based of Cisplatin and Vinorelbine (5 patients) and Cisplatin and Gemcitabine (1 patient). The 4 cycles can be administered without any limiting toxicity only for one patient who’s received 2 cycles of Cisplatin and Gemcitabine in front of the severity of digestive side effects. Two patients considered us IIIB stage, had been surgically treated after neo adjuvant chemotherapy based at Cisplatin and Vinorelbine. Histological response was complete for twice of them. The same chemotherapy was stopped after 2 cycles us adjuvant, in front of haematological side effects. Two patients did at 4 and 15 months of neoplasic progression. The six other patients had been still on life with a move back of 33 months.
Conclusion: Post operative adjuvant chemotherapy is the standard treatment for the II A and II B stages and probably for IB stage. For none immediately operative patients (IIIA and some III B), articulation of chemotherapy with surgery must be clarified.

Keywords:

Lung cancer, surgery, chemotherapy

##plugins.themes.academic_pro.article.details##

References

  1. Parkin DM,Bray F,Ferlay J,Pisani P :Global cancer statisics,2002;CA cancer J Clin 2005;55:74-108.
  2. Hsairi M, Fakhfakh R, Ben Abdallah M , Jelidi R, Sellami A, Nacef T. Assessment of cancer in Tunisia 1993-1997.Tunis Med 2002 ; 80 : 57-64
  3. El Mezni F, Mrabet N, Ismaïl O. Pathological profile of lung carcinoma in Tunisia about 869 cases. Tunis Med 2005; 83: 157-
  4. Fajraoui N, Charfi MR, Khouini H, Annabi H, Bouhaouala MH, Boussen MH.Clinical epidemiology of primary lung cancer in Tunisia .100 cases. Tunis Med 2007; 85: 766-72
  5. Minami H,Yoshimura M,Miyamoto Y,Matsuoka H ,Tsubota N :lung cancer in women :sex associated differences in survival of patients undergoing resection for lung cancer. Chest 2000;118 :1603-9 .
  6. Milleron.B, Gounant .V, Giroux-Leprieur .E, Lavolé. A : La chimiothérapie postopératoire des cancers bronchiques non à petites cellules. Rev. Mal. Resp. 2007 ; 24 : 6S64-68
  7. Westeel.V : La chimiothérapie péri opératoire ces carcinomes bronchiques non à petites cellules. En pratique. Rev. Mal. Resp. Octobre Vol 24 2007 cahier 2 n°8: 6S69-72
  8. Barlesi F.Rev Mal Respir 2006 ;23 :16S47-16S53.
  9. Hamada C , Tanaka F, Ohata M, Fujimura S , Kodama K, Imaizumi M: Meta-analysis of post operative adjuvant chemotherapy with tegafur-uracil in non small cell lung cancer. J Clin Oncol 2005; 23: 4999-5006
  10. Pepe C, Hasan B, Winton T, Seymour L, Pater J, Livingston R; National Cancer Institute of Canada Clinical Trials: Adjuvant chemotherapy in elderly patients : an analysis of national Cancer Institute of Canada Clinical Trials Group and Intergroup BR.10. J Clin Oncol 2006; ASCO Annual Meeting Proceedings Part I. 2006; 24 (185) : 7009
  11. Douillard J, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL: Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non small lung cancer (Adjuvant Navelbine International trialist association (ANITA) : a randomised controlled trial. Lancet Oncol 2006; 7: 719-27.
  12. Depierre.A, Westeel V. La chimiothérapie préopératoire dans les cancers bronchiques non à petites cellules. Rev.Mal.Resp 2007 ;24 : 6S59-63
  13. Pignon J, Triboder H, Scagliotti G, Douillard J, Shepherd F, Stephens R, le chevalier T: Lung adjuvant cisplatin Evaluation (LAEC): a pooled analysis of five randomised clinical trials including 4,584 patients. J. Clin Oncol 2006; 24: 2008.
  14. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J:cisplatin -based adjuvant chemotherapy in patients with completely resected non small cell lung cancer. N Engl J Med 2004; 350: 351-60.
  15. Milleron B, Quoix E, Westeel V, Puyraveau M, Braun D, Breton JL, Bigay-GameL, Pujol JL, Morin F, Depierre A : IFCTOOO2 phase III study comparing a preoperative (PRE) and a perioperative (PERI chemotherapy with two different CT regimens in resectable non small cell lung cancer (NSCLC) : early results. Proc Am Soc Clin Oncol 2007; 25: Abst 7519
  16. Albin KS, Swann RS, Rusch VWet al: Phase III study of concurrent chemotherapy and radiotherapy (CT / RT) vs CT/RT followed by surgical resection for stage III A (pN2) non small cell lung cancer: out comes update of North American inter group 0139 (RTOG 9309). J Clin Oncol 2005; 23 (Suppl): 7014.
  17. Standards Options et Recommandations pour le traitement périopératoire des patients atteints d'un cancer bronchique non à petites cellules résécable d'emblée opérables (mise à jour).Rev Mal Respir 2007 ;24 :1049-64.
  18. Seve P, Issac S, Tredan O, Souquet PJ, Patcheco Y, Perol M et al: Expression of class III (beta) -tubulin is predictive of patient outcome in patients with non small cell lung cancer receiving vinorelbine- based chemotherapy. Clin Cancer Res 2005; 11: 5481-6.
  19. Tsao MS, Aviel- Ronen S, Ding K, Lau D, Liu N , Sakurada A et al : Prognostic and predictive importance of p 53 and RAS for adjuvant chemotherapy in non small cell lung cancer. J Clin Oncol 2007; 25: 5240-7